title: Anti-Ebola MAb 17A3 reacts with bovine and human alpha-2-macroglobulin proteins.
abstract: Monoclonal antibodies (MAbs) were developed against soluble Ebola virus (EBOV) envelope glycoprotein (GP) for the study of the diversity of EBOV envelope and development of diagnostic reagents. Of the three anti-EBOV GP mouse MAbs produced, MAb 15H10 recognized all human EBOV GP species tested (Zaire, Sudan, Ivory Coast), and as well as reacted with the Reston nonhuman primate EBOV GPs. A second MAb, 6D11 recognized EBOV GP species of Sudan and Sudan-Gulu. The third MAb, 17A3, was reported originally in the same article to be EBOV GP specific has now been found to be specific for bovine and human alpha-2-macroglobulin (alpha-2M) proteins which were contaminants in the Ebola envelope protein preparation. Thus, while MAbs 15H10 and 6D11 are indeed EBOV GP specific, MAb 17A3 is an alpha-2-macroglobulin MAb.
authors.affiliation: Departments of Medicine, Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA. yu000022@mc.duke.edu
authors.forename: Jae-Sung
authors.initials: JS
authors.lastname: Yu
authors.forename: Ben-Jiang
authors.initials: BJ
authors.lastname: Ma
authors.forename: Richard M
authors.initials: RM
authors.lastname: Scearce
authors.forename: Hua-Xin
authors.initials: HX
authors.lastname: Liao
authors.forename: Barton F
authors.initials: BF
authors.lastname: Haynes
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D029043:Ebolavirus / Q000276:immunology*; D019142:Hemorrhagic Fever, Ebola / Q000175:diagnosis* / Q000821:virology; D006801:Humans; D051379:Mice; D012680:Sensitivity and Specificity; D014759:Viral Envelope Proteins / Q000276:immunology; D000511:alpha-Macroglobulins / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D014759:Viral Envelope Proteins; D000511:alpha-Macroglobulins; C113189:envelope glycoprotein, Ebola virus
references.citation: Exp Gerontol. 2000 Jul;35(4):473-9
references.pmid: 10959035
references.citation: Lab Invest. 1994 Dec;71(6):792-812
references.pmid: 7528831
references.citation: J Virol Methods. 2006 Nov;137(2):219-28
references.pmid: 16857271
references.citation: J Biol Chem. 2006 Mar 17;281(11):6955-63
references.pmid: 16407218
references.citation: Nat Genet. 1998 Aug;19(4):357-60
references.pmid: 9697696